Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Molecular Cancer volume 22, Article number: 139 (2023)
Correction: Mol Cancer 19, 90 (2020)
Following publication of the original article , the authors do notice that they mis-claimed the qRT-PCR primers that predicted to target human CDH10 gene as specific primers targeting human BIM gene in Materials and methods section when describing quantitative RT-PCR, and the primers have been mis-used to detect mRNA levels of BIM in Fig. 5d, e and h. They are extremely sorry for the misleading caused by this mistake, and to correctly quantify BIM mRNA levels in their tumor cell models, they have re-designed new specific qRT-PCR primers targeting human BIM (forward primer, 5’-TAAGTTCTGAGTGTGACCGAGA-3’, reverse primer, 5’-GCTCTGTCTGTAGGGAGGTAGG-3’), and repeated the qRT-PCR experiments in Fig. 5d, e and h. As shown below, they observed the similar results as our previous data, which was also consistent with the protein levels of Bim previously determined by immunoblotting in Fig. 5d, e and i. They believe that this mistake could be correct and would not affect their critical conclusions in our published paper. The corrected Fig. 5 and updated data of corrected RT-PCR results are provided below.
Cells were treated with DMSO or the indicated compounds for 48 h before being subjected to RNA purification via an EZ-press Cell to cDNA Kit (EZBioscience, #B0001). Samples were then analyzed for mRNA expression via qRT-PCR using the iTaq TM Universal SYBR Ⓡ Green Supermix (BioRad, #1725125) and 7500 real-time PCR instrument (Applied Biosystems). The primer sequences were as follows: BIM, forward primer, 5’-TAAGTTCTGAGTGTGACCGAGA-3’, reverse primer, 5’-GCTCTGTCTGTAGGGAGGTAGG-3’; ACTIN, forward primer, 5’-CACCATTGGCAATGAGCGGTTC-3’, reverse primer, 5’-AGGTCTTTGCGGATGTCCACGT-3’. Primer synthesis was completed by TsingkeBiotechnology.
Zhang T, Qu R, Chan S, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020;19:90. https://doi.org/10.1186/s12943-020-01202-9.
About this article
Cite this article
Zhang, T., Qu, R., Chan, S. et al. Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer 22, 139 (2023). https://doi.org/10.1186/s12943-023-01842-7